Rocaglamide Liposomes, Formulation KHE9A
3295 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 1142 - DLL-0019-1A-25MG
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 25 mg
Parameters
| Additional information | 292 mM sucrose, 0.5% DPBS (1X) |
|---|
DLL-0019-1A-10MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1995 €
DLL-0019-1A-25MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3295 €
DLL-0019-1A-5MG
Rocaglamide Liposomes, Formulation KHE9A
PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1295 €
DLL-0008-1D-100MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3195 €
DLL-0008-1D-10MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
795 €
DLL-0008-1D-25MG
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1195 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Pneumokocker – vad är det som angriper våra barn?
30 August 2025
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Stroke – viktig information
8 August 2025